Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist

被引:15
|
作者
Ohashi, Masao [1 ]
Oyama, Takuji [2 ]
Miyachi, Hiroyuki [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Kita Ku, Okayama 7008530, Japan
[2] Univ Yamanashi, Fac Life & Environm Sci, Dept Biotechnol, Kofu, Yamanashi 4008510, Japan
关键词
PPAR; X-ray crystallographic analysis; Acylsulfonamide derivative; Homodimeric complex; ADIPOGENESIS; ALPHA;
D O I
10.1016/j.bmcl.2015.04.076
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We designed and synthesized acylsulfonamide derivative (3) as a human peroxisome proliferator-activated receptor gamma (hPPAR gamma) partial agonist by structural modification of hPPAR gamma full agonist 1. Co-crystallization of 3 with hPPAR gamma LBD afforded a homodimeric complex, and X-ray crystallographic analysis at 2.1 angstrom resolution showed that one of the LBDs adopts a fully active structure identical with that in the complex of rosiglitazone, a full agonist; however, the other LBD in the complex of 3 exhibits a different (non-fully active) structure. Interestingly, the apo-homodimer contained similar LBD structures. Intrigued by these results, we surveyed reported X-ray crystal structures of partial agonists complexed with hPPAR gamma LBD homodimer, and identified several types of LBD structures distinct from the fully active structure. In contrast, both LBDs in the rosiglitazone complex have the fully active structure. These results suggest hPPAR gamma partial agonists lack the ability to induce fully active LBD. The presence of at least one non-fully active LBD in the agonist complex may be a useful criterion to distinguish hPPAR gamma partial agonists from full agonists. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2639 / 2644
页数:6
相关论文
共 50 条
  • [1] Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist
    Ninomiya, Hiroyo
    Hirata, Ayumu
    Kozawa, Junji
    Nakata, Shinsuke
    Kimura, Takekazu
    Kitamura, Tetsuhiro
    Yasuda, Tetsuyuki
    Otsuki, Michio
    Imagawa, Akihisa
    Kaneto, Hideaki
    Funahashi, Tohru
    Shimomura, Iichiro
    INTERNAL MEDICINE, 2016, 55 (09) : 1143 - 1147
  • [2] Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (γ) Agonist
    Agrawal, R.
    Jain, P.
    Dikshit, S. N.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2012, 12 (02) : 87 - 97
  • [3] Expression and purification of the ligand-binding domain of peroxisome proliferator-activated receptor alpha (PPARα)
    Mueller, Mathias Q.
    Roth, Christian
    Straeter, Norbert
    Sinz, Andrea
    PROTEIN EXPRESSION AND PURIFICATION, 2008, 62 (02) : 185 - 189
  • [4] Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers
    Towfighi, Amytis
    Ovbiagele, Bruce
    CEREBROVASCULAR DISEASES, 2008, 26 (02) : 106 - 112
  • [5] Insights into the mechanism of partial agonism -: Crystal structures of the peroxisome proliferator-activated receptor γ ligand-binding domain in the complex with two enantiomeric ligands
    Pochetti, Giorgio
    Godio, Cristina
    Mitro, Nico
    Caruso, Donatella
    Galmozzi, Andrea
    Scurati, Samuele
    Loiodice, Fulvio
    Fracchiolla, Giuseppe
    Tortorella, Paolo
    Laghezza, Antonio
    Lavecchia, Antonio
    Novellino, Ettore
    Mazza, Fernando
    Crestani, Maurizio
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (23) : 17314 - 17324
  • [6] Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
    Syversen, Unni
    Stunes, Astrid K.
    Gustafsson, Bjorn I.
    Obrant, Karl J.
    Nordsletten, Lars
    Berge, Rolf
    Thommesen, Liv
    Reseland, Janne E.
    BMC ENDOCRINE DISORDERS, 2009, 9
  • [7] Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
    Unni Syversen
    Astrid K Stunes
    Björn I Gustafsson
    Karl J Obrant
    Lars Nordsletten
    Rolf Berge
    Liv Thommesen
    Janne E Reseland
    BMC Endocrine Disorders, 9
  • [8] A SPECIFIC PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)-δ AGONIST ATTENUATES LIVER FIBROGENESIS
    Iwaisako, Keiko
    Taura, Kojiro
    Paik, Yonghan
    Brenner, David A.
    Schnabl, Bernd
    HEPATOLOGY, 2009, 50 (04) : 405A - 406A
  • [9] A partial peroxisome proliferator-activated receptor gamma agonist isolated from the roots of Euphorbia sikkimensis
    He, Liping
    Yuchen, Daili
    Zhang, Shangzhi
    Hui, Yangyang
    Wei, Namei
    He, Yangqing
    NATURAL PRODUCT RESEARCH, 2024, 38 (04) : 656 - 660
  • [10] Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ)-specific agonist, as a modulator in experimental acute pancreatitis
    Celinski, Krzysztof
    Madro, Agnieszka
    Prozorow-Krol, Beata
    Korolczuk, Agnieszka
    Cichoz-Lach, Halina
    Slomka, Maria
    Korobowicz, Elzbieta
    MEDICAL SCIENCE MONITOR, 2009, 15 (01): : BR21 - BR29